To me this looks good, but I wonder what the market will make of this: “An uneven profit profile for CSL is expected for the first and second half results, due to the seasonality of the influenza business and the timing of expenses – particularly research and development,” Mr. Perreault added.
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$247.06 |
Change
-3.600(1.44%) |
Mkt cap ! $119.3B | |||
| Open | High | Low | Value | Volume |
| $250.60 | $251.00 | $245.46 | $100.5M | 407.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 21 | 621 | $247.04 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $247.08 | 82 | 9 |
View Market Depth
| Last trade - 15.36pm 16/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |